AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04387942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
Study NCT02966977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional microbiological identification by culture plate
Description: Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
Study NCT02966977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional microbiological identification by culture plate
Description: Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
Study NCT02966977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct mass spectrometry identification from urine sample
Description: The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
Study NCT02478879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP-PTH
Description: Patch applied daily for 30 minutes, 14 days
Study NCT02478879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FORTEO
Description: Subcutaneous injection administration daily for 14 days
Study NCT00390637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High or low Glycemic Index and high or low Protein Diet
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT03334461 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exposure to oral antiseptics or enamel remineralisation agent
Study NCT04775303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.1% (Ikervis®) eye drop
Description: One drop of Cyclosporine 0.1% (Ikervis®) eye drop once daily for 12 weeks
Study NCT03077139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
Study NCT01153373 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.
Description: All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only.
Study NCT01153373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse
Description: All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
Study NCT03993379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Description: CX-072 in combination with ipilimumab
Study NCT03993379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CX-072 in combination with ipilimumab
Study NCT02308995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy using barbed sutures
Description: A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
Study NCT02308995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystectomy using conventional sutures
Description: A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
Study NCT02308995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Loc (Covidien, Mansfield, MA)
Study NCT02308995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)
Study NCT03900455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocellular polyurethane foam multilayer dressing
Description: Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
Study NCT03900455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard preventive care
Description: Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
Study NCT03900455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard preventive care
Description: Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
Study NCT01256879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: cimetidine
Description: cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
Study NCT01256879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: cimetidine
Description: cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
Study NCT01679652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Tablet i blinded in capsula
Study NCT01679652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02859142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
Study NCT02859142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling Sessions
Description: One-to-one behavioral counseling sessions with a trained therapist
Study NCT02859142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Counseling Sessions
Description: One-to-one behavioral counseling sessions with a trained therapist
Study NCT02859142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicodermCQ
Description: Nicotine patches provided over 12 week participation
Study NCT02859142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicodermCQ
Description: Nicotine patches provided over 12 week participation
Study NCT02859142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
Study NCT06328465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diffusion whole body MRI
Description: Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
Study NCT03062384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AT-001
Study NCT03062384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01527409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored health partnership program
Description: When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement.
Study NCT01527409 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Usual care and health education workshop
Description: While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group.
Study NCT01412086 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: No Intervention.
Study NCT00463749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcystein
Description: high-dose N-Acetylcystein during PCI and for 2/day for 2 days
Study NCT00463749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl as placebo
Study NCT04244513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
Study NCT04244513 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
Study NCT00914862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets, orally for one day only.
Study NCT00914862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: Ramelteon tablets, orally for one day only.
Study NCT03178747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: working solution methylene blue
Study NCT03178747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Methylene blue
Description: working solution methylene blue
Study NCT03178747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Giemsa stain
Description: working solution Giemsa stain (Wolbach's modification)
Study NCT03178747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Giemsa stain
Description: working solution Giemsa stain (Wolbach's modification)
Study NCT04263701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: Conventional physiotherapy exercises for children with cerebral palsy
Study NCT04263701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
Study NCT03830554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic Atlas cedar wood essential oil (Cedrus Atantica)
Description: At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
Study NCT01141881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator,bevacizumab ,follow up
Description: 25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
Study NCT04242004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) capsules
Description: Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
Study NCT04242004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy oil capsules
Description: The placebo was identical looking capsules that contained soy oil
Study NCT03198741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin + clopidogrel
Description: After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
Study NCT03198741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Description: After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
Study NCT03198741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin monotherapy
Description: After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
Study NCT01324388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously
Study NCT01324388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Administered orally
Study NCT01324388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Administered orally
Study NCT01324388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Administered orally
Study NCT01324388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT00728130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck dissection of at least the ipsilateral sub-level 1B
Description: neck dissection of at least the ipsilateral sub-level 1B
Study NCT01715311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol once daily via single-dose dry powder inhaler
Study NCT01715311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsules for inhalation once daily
Study NCT01715311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsules for inhalation once daily
Study NCT01715311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium capsules for inhalation once daily
Study NCT01715311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol capsules for inhalation once daily
Study NCT01715311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol capsules for inhalation once daily
Study NCT03760120 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PEP-MASK
Study NCT03760120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP-MASK
Study NCT02044133 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dosage Vitamine D
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Study NCT02237937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Study NCT05982002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave
Description: ESWT (Chattanooga, Intelect RPW, USA) continues mode, hand piece transmitter R SW D20 /20mm, with the following Parameter: Shock pressure of 3-4 bars, wave frequency of 12 Hz.
Study NCT05982002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity aerobic exercise
Description: Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
Study NCT05982002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Description: Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
Study NCT02402283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole benzoate oral granules
Description: Single oral dose of 400 mg
Study NCT02402283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl 400 mg Tablets
Description: Single oral dose of 400 mg
Study NCT04407234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide administered SC.
Study NCT04407234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen administered orally.
Study NCT01705912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete intervention
Description: The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
Study NCT01705912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic intervention
Description: The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
Study NCT02262754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
Study NCT02262754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06372865 and placebo for naproxen daily
Study NCT02262754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500 mg BID for 4 weeks
Study NCT01858753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fibroblasts
Study NCT01858753 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous fibroblasts
Study NCT01858753 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo sterile saline